Wells Fargo & Company Cellectis S.A. Transaction History

Wells Fargo & Company

$434 Billion
Q3 2024

A detailed history of Wells Fargo & Company transactions in Cellectis S.A. stock. As of the latest transaction made, Wells Fargo & Company holds 12,090 shares of CLLS stock, worth $18,981. This represents 0.0% of its overall portfolio holdings.

Number of Shares

12,090

Previous 12,790 5.47%

Holding current value

$18,981

Previous $23,000 8.7%

% of portfolio

0.0%

Previous 0.0%

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	SELL	$1.9 - $2.4 $1,330 - $1,680	-700 Reduced 5.47%	12,090 $25,000
Q2 2024 Aug 13, 2024	SELL	$1.86 - $3.35 $279 - $502	-150 Reduced 1.16%	12,790 $23,000
Q1 2024 May 10, 2024	SELL	$2.41 - $3.09 $3,263 - $4,183	-1,354 Reduced 9.47%	12,940 $34,000
Q4 2023 Feb 09, 2024	SELL	$0.97 - $3.55 $1,212 - $4,437	-1,250 Reduced 8.04%	14,294 $44,000
Q3 2023 Nov 13, 2023	SELL	$1.58 - $2.86 $592 - $1,072	-375 Reduced 2.36%	15,544 $24,000
Q2 2023 Aug 15, 2023	SELL	$1.72 - $2.12 $963 - $1,187	-560 Reduced 3.4%	15,919 $31,000
Q1 2023 May 12, 2023	SELL	$1.83 - $3.84 $915 - $1,920	-500 Reduced 2.94%	16,479 $31,000
Q4 2022 Feb 13, 2023	SELL	$1.85 - $2.6 $462 - $650	-250 Reduced 1.45%	16,979 $35,000
Q3 2022 Nov 14, 2022	BUY	$2.29 - $4.08 $12,366 - $22,032	5,400 Added 45.65%	17,229 $40,000
Q2 2022 Aug 12, 2022	SELL	$2.39 - $4.93 $2,629 - $5,423	-1,100 Reduced 8.51%	11,829 $33,000
Q1 2022 May 16, 2022	SELL	$3.45 - $8.77 $22,573 - $57,382	-6,543 Reduced 33.6%	12,929 $59,000
Q4 2021 Feb 14, 2022	SELL	$8.01 - $12.84 $113,325 - $181,660	-14,148 Reduced 42.08%	19,472 $158,000
Q3 2021 Nov 15, 2021	BUY	$11.94 - $16.09 $55,998 - $75,462	4,690 Added 16.21%	33,620 $423,000
Q2 2021 Aug 16, 2021	SELL	$14.36 - $20.93 $22,143 - $32,274	-1,542 Reduced 5.06%	28,930 $448,000
Q1 2021 May 13, 2021	BUY	$18.19 - $33.25 $66,211 - $121,030	3,640 Added 13.57%	30,472 $616,000
Q4 2020 Feb 09, 2021	SELL	$15.87 - $31.64 $21,662 - $43,188	-1,365 Reduced 4.84%	26,832 $726,000
Q3 2020 Nov 05, 2020	SELL	$15.7 - $20.84 $41,934 - $55,663	-2,671 Reduced 8.65%	28,197 $522,000
Q2 2020 Aug 13, 2020	SELL	$8.21 - $21.02 $58,980 - $151,007	-7,184 Reduced 18.88%	30,868 $550,000
Q1 2020 May 14, 2020	BUY	$7.81 - $18.82 $297,186 - $716,138	38,052 New	38,052 $350,000

Others Institutions Holding CLLS

# of Institutions

Shares Held

10.8M

Call Options Held

5.9K

Put Options Held

1.4K

View Full List

About Cellectis S.A.

Ticker CLLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,510,800
Market Cap $71.5M
Description
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatm...

More about CLLS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.

Account

Wells Fargo & Company Cellectis S.A. Transaction History